An observational study in CHB, sponsored by Beijing Municipal Administration of Hospitals. Completed at 1 site in China. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Beijing Municipal Administration of Hospitals · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 377 studies in Hepatitis B, Chronic with a site in China — 90 open to participants now, 111 under way, 7 of them phase 3. Hepatitis B, Chronic · China.
Among the 377 studies in Hepatitis B, Chronic with a site in China, this one is the 92nd largest by enrollment of the 100 observational ones that give a count, is one of 24 that started in 2025, is one of 100 observational ones, and was the 375th registered.
898 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →90 of the 377 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:
Jiyan Liu · Sites in China
Ages 18–65
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Fujian Akeylink Biotechnology Co., Ltd. · Sites in China
Ages 35–65
Ausper Biopharma Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Fujian Akeylink Biotechnology Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 30 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
377 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 63 · Phase 2 85 · Phase 3 27 · Phase 4 73
First in 2000; this study’s year is marked. 24 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 99 is below the median of 400 across 208 observational studies indexed under Hepatitis B, Chronic.
Median enrollment 120 across the 274 interventional studies, 500 across the 100 observational. Of the 152 that completed or were terminated, 29 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
168 of 377 have an industry lead sponsor. The 10 most frequent:
Beijing Municipal Administration of Hospitals is the lead sponsor of 16 studies on the registry; 10 are open to participants now.
Beijing Municipal Administration of Hospitals has 6 studies filed under Hepatitis B, Chronic — fewer than ten, so there is no comparison to draw.
40 of the studies in Hepatitis B, Chronic with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07090759Phase 3Fujian Akeylink Biotechnology Co., Ltd.To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment | 2026-12-01 |
| NCT07246889Phase 3Ausper Biopharma Co., Ltd.Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) | 2026-12-18 |
| NCT07307586Phase 3Zhigang RenA Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis B | 2026-12-31 |
| NCT07203118Phase 3Xi'an Xintong Pharmaceutical Research Co.,Ltd.A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B | 2027-06-30 |
| NCT02863757Humanity and Health Research CentreFollow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease | 2026-12 |
Add all 40 to your calendar (.ics) → With an account.
Among the 377 studies in Hepatitis B, Chronic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Existing studies have confirmed that there are differences in the methylation status of liver tissue due to hepatitis B virus infection and alcohol consumption. There are also differences in the methylation status at each stage of the disease progression from hepatitis to liver cirrhosis and then to liver cancer. However, no study has systematically compared the cfDNA methylation profiles of hepatitis B subjects under different alcohol consumption statuses. Plasma cfDNA methylation detection has been proven to be applicable for the early warning of HBV - related liver cancer and has the characteristics of being non - invasive and allowing dynamic monitoring. However, most of the existing markers focus on the "liver cancer transformation" stage, and there is a lack of typing markers suitable for the early stage of "hepatitis progression". To preliminarily explore this field, this project was initiated.
This study is an observational and exploratory study that does not involve clinical treatment intervention for the subjects. The project plans to enroll 85 subjects with chronic hepatitis B. They will be divided into a non - drinking group, a drinking group, and a group that has developed alcoholic hepatitis due to alcohol consumption according to the degree of alcohol consumption. For each patient, 2 tubes of peripheral blood (about 8 mL per tube), a total of about 16 mL, will be collected for cfDNA methylation analysis. By comparing the plasma cfDNA methylation profiles of chronic hepatitis B subjects with different degrees of alcohol consumption, the impact of different degrees of alcohol consumption on the cfDNA methylation of the subjects will be analyzed.
The study subjects were all inpatients and outpatients with chronic hepatitis B who visited the Second Department of Hepatology at Beijing Ditan Hospital, Capital Medical University, from November 21, 2025, to May 31, 2026. The subjects were grouped according to their drinking status into a non - drinking group, a drinking group, and a group that progressed to alcoholic hepatitis. The inclusion criteria are as follows: (1) Age between 30 and 75 years old (inclusive of 30 but exclusive of 75); (2) Subjects diagnosed with chronic hepatitis B; (3) Signed the informed consent form and were willing to follow the sampling and evaluation procedures of this study. The exclusion criteria include: (1) Patients with liver cirrhosis; (2) Pregnant and lactating women; (3) Subjects with a history of cancer in the past or at the time of screening; (4) A history of severe acute infectious diseases within 14 days before screening (such as severe and critical COVID - 19 infection, sepsis, etc.); (5) Use of the following drugs within 14 days before screening: intravenous/oral use of glucocorticoids; intravenous/oral use of azacitidine, decitabine, procainamine, hydrazine, arsenic trioxide; (6) Subjects who had undergone organ transplantation, bone marrow transplantation, stem - cell transplantation before screening or had received blood transfusion within 30 days before screening; (7) Other situations judged by the researcher as unsuitable for participation in this study.
Considering the practical feasibility of the study and the calculation of the sample size, a sufficient number of samples need to be collected clinically to observe whether there are statistically significant differences. 25 cases were set in the non - drinking group and 50 cases in the drinking group. This sample size has 80% statistical power at a significance level of 0.05, which can detect moderately large differences, that is, we consider there are biologically meaningful differences. In addition, 10 cases of patients who progressed to alcoholic hepatitis were additionally collected, which was only for exploration and not based on precise formula calculations. Substituting the sample sizes of 25 non - drinking and 50 drinking cases, Cohen's d = 0.69, that is, the difference between the two groups is about 0.69 standard deviations. Under a two - sided test with α = 0.05, 80% statistical power can be achieved. Considering clinical practice and the enrollment path, there may be a certain dropout rate, estimated to be about 35%. Therefore, the actual number of blood samples to be collected is estimated to be about 130 cases.
Grouping description: (1) Non - drinking group: Drinking less than 2 times a year, with no limit on the amount of alcohol per time; (2) Drinking group: An average of at least 50g of alcohol per day. After the subjects pass the preliminary inclusion and exclusion review, pre - enrollment sampling is carried out. After collecting the imaging and blood test report information, it is confirmed whether the subject meets the enrollment and disease classification information, and the information collection and entry are completed.
Blood sample collection: Use disposable free DNA storage tubes to collect 2 tubes of whole - blood samples, 8 - 10 mL per tube. After collecting the whole - blood samples, number, label, and register them, and then transport the samples as required below. The collector disinfects the puncture site with iodine. Use a disposable free DNA storage tube to collect whole blood until there is no negative pressure (the volume of whole blood is 8 - 10 mL), gently invert and mix about 10 times. Collect 2 tubes of whole blood using a disposable free DNA storage tube as described above. Transport at room temperature (6 - 37°C). In case of extreme weather, remote areas, or other force majeure, professional cold chain transportation can be selected. After the collected blood samples arrive at the third - party testing laboratory (Shanghai Xiaohe Medical Laboratory Co., Ltd.), the plasma will be centrifuged and separated, and cfDNA will be extracted. After a series of experimental treatments such as methylation conversion, methylation DNA library construction, and hybridization capture, the NGS platform is used to detect the methylation level of cfDNA.
The complete statistical analysis includes statistics on inclusion and exclusion during screening, statistics on exclusions, and analysis of the main evaluation indicators. The main indicators to be described include the differential methylation profiles of cfDNA among groups with different drinking levels. Data analysis is performed using SPSS (v29) software for corresponding calculations. All statistical tests in this study use two - sided tests, and a p - value less than or equal to 0.05 will be considered statistically significant. All confidence intervals are estimated using 95% two - sided results.
The study consists of two phases, including the subject screening phase and the sampling phase. Screening phase: Enroll patients clinically diagnosed with chronic hepatitis B who meet the inclusion criteria as evaluated by the researcher, complete the informed consent for the clinical study, and sign the informed consent form. During the screening phase, basic information of the subjects, such as past medical history, medication, drinking, and demographic information, needs to be collected. Sampling phase: After pre - enrollment, 2 tubes of peripheral blood (about 8 mL per tube, a total of about 16 mL) are collected from the subjects for laboratory testing, and basic information such as the subjects' drinking habits and family history is collected. For all subjects, the blood and imaging test results from 6 months before pre - enrollment or 1 month after enrollment will also be collected, including indicators of chronic hepatitis B infection, liver function indicators, liver fibrosis indicators, and liver imaging examination data. If there are multiple test results, only the most recent test result before enrollment needs to be collected.
The study samples are fresh blood samples collected from subjects after signing the informed consent. The clinical information mainly comes from the HIS system. A case information collection form has been designed to collect the results of blood, imaging, and other indicators related to the subjects' chronic hepatitis B examinations.
The study subjects were all inpatients and outpatients with chronic hepatitis B who visited the Second Department of Hepatology at Beijing Ditan Hospital, Capital Medical University, from November 21, 2025, to May 31, 2026. The subjects were grouped according to their drinking status into a non - drinking group, a drinking group, and a group that progressed to alcoholic hepatitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drink less than twice a year, with no limit on the amount of alcohol consumed each time.
An average of at least 50 g per day.
cfDNA methylation
Plasma cell-free DNA methylation profile
Time frame: through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2025 to primary completion in May 2026, 6 months.
Of 72 observational studies under Hepatitis B, Chronic, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 99. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Municipal Administration of Hospitals